A miRNA-based Signature Predicts Development of Disease Recurrence in HER2 Positive Breast Cancer After Adjuvant Trastuzumab-Based Treatment
Scientific Reports - United Kingdom
doi 10.1038/srep33825
Full Text
Open PDFAbstract
Available in full text
Categories
Date
September 1, 2016
Authors
Publisher
Springer Science and Business Media LLC